Current Setup & Catalysts
Current Setup & Catalysts
1. Current Setup in One Page
The stock is in the middle of a regime-change tape: SKC has rallied roughly +75% in six weeks into a ₩1.0 trillion rights-offering close on 8 June 2026, while consensus is still printing UNDERPERFORM at ₩105,864. The market is watching three things at once — (i) does the 1Q26 EBITDA inflection hold in 2Q?, (ii) does the rights offering price as a clearing event or as a fresh dilution shock?, and (iii) does Absolics actually convert glass-substrate sample work into a named hyperscaler qualification by year-end? Three years of guidance misses, a CEO change six weeks ago, and a 30-day realised vol of 117% mean every print over the next 90 days will be marked harder than usual. The next 6 months are unusually event-rich for a Korean specialty-materials mid-cap; the calendar is not thin, but it is binary.
Recent Setup Rating: Mixed
Hard-Dated Events (6mo)
High-Impact Catalysts
Days to Next Hard Date
Spot (₩, 2026-05-08)
Last Session %
30d Realised Vol (%)
Implied Upside vs Consensus
Single highest-impact near-term event: the 8 June 2026 new-share listing of the ₩1T rights offering. Subscription pricing finalises in mid-May, existing shareholders subscribe 14–15 May 2026, and the new shares list 30 days from today. The clearing — or failure — of this issue is the dominant variable for the next 30 days; the 2Q 2026 EBITDA print on or around 5 August is the dominant variable for days 60–90.
2. What Changed in the Last 3-6 Months
The narrative arc. Three months ago the question was whether SKC could survive the cycle without further dilution and whether legacy losses would compound — both ostensibly answered by the 26 February rights announcement and the 5 February FY25 reset. Today the question is the opposite: whether the recent ₩50K rally (₩105K → ₩160K) has run ahead of the deliverables. Unresolved variables sit on the operating side: chemicals at risk of reverting if Mid-East PG tightness fades, copper-foil processing fees not yet recovering, Absolics pre-revenue with no named hyperscaler. The ₩594 bn FY25 below-the-line loss block — ~3× the operating loss — has not been disaggregated in English filings, leaving the consolidated burn mis-measured by anyone outside DART Korea.
3. What the Market Is Watching Now
The live debate is unusual: the consensus is bearish (UNDERPERFORM), the tape is screaming bullish (+75% in six weeks), and the company is days away from issuing 22% new shares. All three positions cannot be right. The next 30–90 days resolve which one was.
4. Ranked Catalyst Timeline
Reading the timeline. Five of the top six catalysts land in the next 6 months — three of them inside 90 days. This is not a thin calendar. The unusual feature is that the three calendar-confirmed events (rights subscription, listing, Q2 earnings) sit before the soft window for Absolics qualification, so the underwriting question gets answered in chronological order: first whether the dilution is absorbed, then whether the operations sustain, and only then whether the optionality pays.
5. Impact Matrix
The matrix concentrates on resolution power, not information value. The rights close and the 2Q print collectively decide whether the bull rally extends or unwinds; the Absolics qualification window decides whether the dilution paid; the ISC multiple decides whether the SOTP stays intact through any of the above. Items further down add flavour but do not, on their own, force the debate to update.
6. Next 90 Days
The next 90 days are the densest window in SKC's calendar in three years. Two hard-dated capital-allocation milestones (rights subscription + new-share listing) bracket a single hard-dated earnings event (2Q 2026), with the live ISC mark-to-market running through every day of that window. There is no realistic case in which no new information arrives.
7. What Would Change the View
The two or three observable signals that would most change the investment debate over the next six months are: (1) the 8 June listing-day tape, because a clean clearing turns the dilution from an overhang into a recap and removes the single most-cited reason consensus targets sit at ₩105K; (2) the 2Q 2026 EBITDA print on or around 5 August, because a second consecutive positive print converts 1Q26 from "flattering 4Q big-bath comp" into "structural inflection," the precise question the bear case rests on (forensics-claude.md scorecard B7); and (3) any named hyperscaler qualification at Absolics in 2H26, because that is the only catalyst that can re-rate the ₩590B of dilution proceeds from sunk cost to optioned upside — and is also the binary cover signal the bear case names explicitly. Secondary signals worth tracking are an ISC standalone compression of 20%+ on AI capex doubt (which would test the SOTP simultaneously with operations), an adverse copper-foil patent ruling (which would compound SK nexilis loss exposure not currently in sell-side models), and a sell-side revision wave that pulls Nomura's ₩90K or JPMorgan's ₩72K targets toward spot (which would mean the institutional underwriting that has been absent finally arrives). What would not change the view: another disposal, another SK-affiliate-led capital injection, or an investor-day deck — those are continuations of the 2025 pattern, not new information.